Globe Life Posts 10% EPS Gain in Q2

Globe Life (NYSE:GL) reported Q2 2025 adjusted EPS of $3.27, surpassing analyst estimates and growing 10% year-over-year, despite GAAP revenue of $1.48 billion missing expectations and a 19% decline in excess investment income. Management reaffirmed full-year 2025 EPS guidance, citing confidence in operational strength, particularly in life insurance which saw a 6% increase in underwriting margin and strong agent growth, even as health segment margins faced pressure. This ability to maintain its outlook despite revenue softness and investment income headwinds signals resilience in core insurance operations.

Analysis

Globe Life (GL) reported a mixed but fundamentally resilient second quarter for 2025, characterized by strong bottom-line execution overshadowed by top-line softness and investment income headwinds. The company's adjusted EPS grew 10% year-over-year to $3.27, narrowly beating analyst estimates, a performance driven primarily by the strength of its core life insurance operations. The life segment, which constitutes 78% of underwriting margin, saw its margin expand by 6%, reflecting favorable mortality trends and robust premium growth. This operational strength, combined with an aggressive $226 million share repurchase, was sufficient to offset a miss on GAAP revenue, which came in at $1.48 billion versus a $1.51 billion estimate, and a significant 19% year-over-year decline in excess investment income. While the health segment's underwriting margin contracted by 2% due to pressures in the Medicare supplement business, management's reaffirmation of its full-year EPS guidance of $14.25 to $14.65 signals strong confidence. This confidence appears rooted in expectations for continued strength in life margins, including a potential $60 million to $100 million remeasurement gain in Q3, and positive momentum in agent count growth, which bodes well for future sales. However, investors must note the persistent, albeit non-materially updated, risk from ongoing SEC and DOJ inquiries.

Key Decisions for Investors

• Investors should weigh the company's demonstrated ability to grow EPS and reaffirm guidance against the clear headwinds of a revenue miss and a 19% drop in excess investment income.
• Monitor agent count growth and life insurance underwriting margins in H2 2025, as these are the key drivers management is relying on to meet its reaffirmed full-year guidance.
• Consider the capital return program, with $226 million in Q2 buybacks supporting the share price, but remain cautious due to the unquantified tail risk from the ongoing SEC and DOJ investigations.
• Factor in the divergent performance between the robust life insurance segment and the pressured health segment, whose margins are not expected to normalize until 2026.